We examine the design of loan contract terms in the presence of borrower preissuance real earnings management (REM). Unlike other measures of earnings quality, REM is particularly difficult for outsiders to detect. However, lenders possess some private information which may allow them to correctly identify REM. Our empirical findings show that greater REM is associated with higher interest spreads, shorter maturities, a higher likelihood of imposing collateral requirements, and more intensive financial covenants, suggesting that lenders are likely to detect and penalise the borrower firm's REM activities.These findings are robust to a series of sensitivity tests. In an additional test, we examine the impact of REM on bond terms and document that greater REM is related to higher bond yield spreads and more intensive covenants, but does not affect the maturity term or the collateral requirement. The findings in this paper can alert firms about the increase in borrowing costs when they use REM to boost current-period earnings.
This paper is an empirical examination of the relative roles of agency and tax considerations in corporate debt versus equity issuance decisions. Unlike earlier work, we conduct our tests on a sample of UK firms since the UK system of taxation does not create an obvious tax advantage to debt and hence affords an opportunity to evaluate the relevance of tax arbitrage considerations. We find that both tax and agency issues are important determinants of security issuance decisions. In addition, we demonstrate that our specification is robust to a variety of alternative explanations which have appeared in the empirical literature. Copyright Blackwell Publishers Ltd 1997.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.